Table 1: Marketed Antiplatelet Agents that Inhibit Platelet Activation
Table 2: Marketed Anticoagulants that Inhibit the Coagulatory Cascade
Table 3: Antidyslipidemic agents
Table 4: Classifications of ACS
Table 5: Universal Classification of MI
Table 6: Symptoms of Acute Coronary Syndrome
Table 7: Risk Factors and Comorbidities for ACS
Table 8: Global, Crude Total Population Prevalence Percentages of Angina Pectoris and Mean Age of Study Participants
Table 9: 7MM, Sources of Diagnosed Prevalence Data for MI
Table 10: 7MM, Data Sources of STEMI and NSTEMI Proportions Among Diagnosed Prevalent Cases of MI
Table 11: 7MM, Data Sources of ACS Hospitalizations
Table 12: 7MM, Data Sources of STEMI and NSTEMI Proportions Among MI Hospitalizations
Table 13: 7MM, Diagnosed Prevalent Cases of ACS, Ages =25 Years, Both Sexes, N, Select Years, 2015–2025
Table 14: 7MM, Age-Specific Diagnosed Prevalent Cases of ACS, Men and Women, N (Row %), 2015
Table 15: 7MM, Sex-Specific Diagnosed Prevalent Cases of ACS, Ages =25 Years, N (Row %), 2015
Table 16: 7MM, Diagnosed Prevalent Cases of STEMI, NSTEMI, and UA, Ages =25 Years, N (Row %), 2015
Table 17: 7MM ACS Hospitalizations, Ages =25 Years, Both Sexes, N, Select Years, 2015–2025
Table 18: 7MM, Sex-Specific ACS Hospitalizations, Ages =25 Years, N (Row %), 2015
Table 19: 7MM, Diagnosed ACS Hospitalizations Segmented by STEMI, NSTEMI and UA, Ages =25 Years, Both Sexes, N, 2015
Table 20: Most-Prescribed Drugs for ACS by Class in the Global Markets, 2015
Table 21: Treatment Guidelines for Acute Coronary Syndromes (UA, NSTEMI, and STEMI)
Table 22: Country Profile for ACS – US
Table 23: Country Profile for ACS – 5EU
Table 24: Country Profile for ACS – Japan
Table 25: Leading Treatments for ACS, 2015
Table 26: Commonly Used Beta Blockers
Table 27: Product Profile – Beta Blockers
Table 28: Beta Blockers SWOT Analysis, 2015
Table 29: Global ACS Sales Forecasts [$m] for Beta Blockers, 2015–2025
Table 30: Commonly Used ACE Inhibitors
Table 31: Product Profile – ACE Inhibitors
Table 32: ACE Inhibitor?SWOT Analysis, 2015
Table 33 Global ACS Sales Forecasts [$m] for ACE inhibitors, 2015–2025
Table 34: Commonly Used ARBs
Table 35: Product Profile – Angiotensin Receptor Blockers (ARBs)
Table 36: ARB SWOT Analysis, 2015
Table 37: Global ACS Sales Forecasts [$m] for ARBs, 2015–2025
Table 38: Product Profile – Mineralocorticoid Receptor Antagonists (MRAs)
Table 39: MRA SWOT Analysis, 2016
Table 40: Global ACS Sales Forecasts [$m] for MRAs, 2015–2025
Table 41: Product Profile – Warfarin
Table 42: Warfarin SWOT Analysis, 2015
Table 43: Global ACS Sales Forecasts [$m] for Warfarin, 2015–2025
Table 44: Product Profile – Angiomax
Table 45: AngiomaxSWOT Analysis, 2015
Table 46: Global ACS Sales Forecasts [$m] for Angiomax, 2015–2025
Table 47: Product Profile – Fondaparinux
Table 48: Arixtra SWOT Analysis, 2015
Table 49: Global ACS Sales Forecasts ($M) for Fondaparinux, 2015–2025
Table 50: Product Profile – Xarelto (rivaroxaban)
Table 51: Xarelto SWOT Analysis, 2015
Table 52: Global ACS Sales Forecast ($M) for Xarelto, 2015–2025
Table 53: Commonly Used tPAs
Table 54: Product Profile – Tissue Plasminogen Activator (tPA)
Table 55: Fibrinolytics?SWOT Analysis, 2015
Table 56: Global ACS Sales Forecast ($M) for Fibrinolytics, 2015–2025
Table 57: Product Profile – Repatha (Evolocumab)
Table 58: Product Profile – Praluent (Alirocumab)
Table 59: PCSK9 inhibitors SWOT Analysis, 2015
Table 60: Global ACS Sales Forecasts [$m] for Repatha, 2015–2025
Table 61: Global ACS Sales Forecasts [$m] for Praluent, 2015–2025
Table 62: Product Profile – Atorvastatin
Table 63: Product Profile – Simvastatin
Table 64: Lipitor (Atorvastatin) SWOT Analysis, 2015
Table 65: Zocor (Simvastatin) SWOT Analysis, 2015
Table 66: Global ACS Sales Forecasts [$m] for Generic Statins, 2015–2025
Table 67: Product Profile – Crestor (Rosuvastatin)
Table 68: Crestor (Rosuvastatin) SWOT Analysis, 2015
Table 69: Global ACS Sales Forecasts [$m] for Crestor, 2015–2025
Table 70: Product Profile – Clopidogrel
Table 71: Clopidogrel SWOT Analysis, 2015
Table 72: Global ACS Acute Phase Sales Forecast ($M) for Clopidogrel, 2015–2025
Table 73: Global ACS Chronic Phase Sales Forecasts ($M) for Clopidogrel, 2015–2025
Table 74: Product Profile – Brilinta (ticagrelor)
Table 75: Brilinta (ticagrelor) SWOT Analysis, 2015
Table 76: Global Acute Phase ACS Sales Forecast ($M) for Brilinta, 2015–2025
Table 77: Global ACS Chronic Phase Sales Forecast ($M) for Brilinta, 2015–2025
Table 78: Product Profile – Effient (Prasugrel)
Table 79: Effient (Prasugrel) SWOT Analysis, 2015
Table 80: Global Acute Phase ACS Sales Forecast ($M) for Effient, 2015–2025
Table 81: Global ACS Chronic Phase Sales Forecast ($M) for Effient, 2015–2025
Table 82: Product Profile – Integrilin (Eptifibatide)
Table 83: Integrilin (Eptifibatide) SWOT Analysis, 2015
Table 84: Global ACS Sales Forecast ($M) for Integrilin, 2015–2025
Table 85: Product Profile – Cangrelor
Table 86: Kengreal (cangrelor) SWOT Analysis, 2015
Table 87: Global ACS Sales Forecasts ($M) for Kengreal, 2015–2025
Table 88: Product Profile – Zontivity (Vorapaxar)
Table 89: Vorapaxar SWOT Analysis, 2015
Table 90: Global ACS Sales Forecast ($M) for Zontivity, 2015–2025
Table 91: Unmet Need and Opportunity in ACS
Table 92: Comparison of Therapeutic Classes in Development for ACS, 2015
Table 93: Comparison of Therapeutic Classes in Pipeline for ACS, 2016
Table 94: Product Profile – Bococizumab (PF-04950615)
Table 95: Bococizumab (PF-04950615) SWOT Analysis, 2015
Table 96: Global ACS Sales Forecasts [$m] for Bococizumab, 2015–2025
Table 97: Product Profile – Anacetrapib
Table 98: Anacetrapib SWOT Analysis, 2015
Table 99: Global ACS Sales Forecasts [$m] for Anacetrapib, 2015–2025
Table 100: Product Profile – CSL-112
Table 101: CSL-112 SWOT Analysis, 2015
Table 102: Global ACS Sales Forecasts [$m] for CSL-112, 2015–2025
Table 103: Product Profile – CER-001
Table 104: CER-001 SWOT Analysis, 2015
Table 105: Global ACS Sales Forecasts [$m] for CER-001, 2015–2025
Table 106: Product Profile – LY3015014
Table 107: LY3015014 SWOT Analysis, 2015
Table 108 Global ACS Sales Forecasts [$m] for LY3015014 , 2015–2025
Table 109: Product Profile – AMG-899
Table 110: AMG-899 SWOT Analysis, 2015
Table 111: Global ACS Sales Forecasts [$m] for AMG-899, 2015–2025
Table 112: Product Profile – ETC-1002
Table 113: ETC-1002 SWOT Analysis, 2016
Table 114: Global ACS Sales Forecasts [$m] for ETC-1002, 2015–2025
Table 115: Key Companies in the ACS Market, 2016
Table 116: Amgen’s ACS Portfolio Assessment, 2016
Table 117: AstraZeneca’s ACS Portfolio Assessment, 2015
Table 118: BMS’s ACS Portfolio Assessment, 2015
Table 119: Cerenis’ ACS Portfolio Assessment, 2015
Table 120: CSL Limited’s ACS Portfolio Assessment, 2015
Table 121: Daiichi Sankyo’s ACS Portfolio Assessment, 2015
Table 122: Eli Lilly’s ACS Portfolio Assessment, 2015
Table 123: Esperion’s ACS Portfolio Assessment, 2016
Table 124: GlaxoSmithKline’s Acute Coronary Syndrome Portfolio Assessment, 2015
Table 125: Janssen’s ACS Portfolio Assessment, 2015
Table 126: The Medicines Company’s Acute Coronary Syndrome Portfolio Assessment, 2015
Table 127: Merck’s ACS Portfolio Assessment, 2015
Table 128: Pfizer’s ACS Portfolio Assessment, 2015
Table 129: Sanofi’s ACS Portfolio Assessment, 2015
Table 130: Global Sales Forecasts [$m] for Acute Coronary Syndrome, 2015–2025
Table 131: ACS Global market – Drivers and Barriers, 2015–2025
Table 132: Sales Forecasts [$m] for Acute Coronary Syndrome in the US, 2015–2025
Table 133: Key Events Impacting Sales for ACS in the US, 2015–2025
Table 134: US ACS Market – Drivers and Barriers, 2015–2025
Table 135: Sales Forecasts [$m] for Acute Coronary Syndrome in France, 2015–2025
Table 136: Key Events Impacting Sales for ACS in France, 2015–2025
Table 137: France ACS market – Drivers and Barriers, 2015–2025
Table 138: Sales Forecasts [$m] for Acute Coronary Syndrome in Germany, 2015–2025
Table 139: Key Events Impacting Sales for ACS in Germany, 2015–2025
Table 140: Germany ACS market – Drivers and Barriers, 2015–2025
Table 141: Sales Forecasts [$m] for Acute Coronary Syndrome in Italy, 2015–2025
Table 142: Key Events Impacting Sales for ACS in Italy, 2015–2025
Table 143: Italy ACS market – Drivers and Barriers, 2015–2025
Table 144: Sales Forecasts [$m] for Acute Coronary Syndrome in Spain, 2015–2025
Table 145: Key Events Impacting Sales for ACS in Spain, 2015–2025
Table 146: Spain ACS Market – Drivers and Barriers, 2015–2025
Table 147: Sales Forecasts [$m] for Acute Coronary Syndrome in the UK, 2015–2025
Table 148: Key Events Impacting Sales for ACS in the UK, 2015–2025
Table 149: UK ACS market – Drivers and Barriers, 2015–2025
Table 150: Sales Forecasts [$m] for Acute Coronary Syndrome in Japan, 2015–2025
Table 151: Key Events Impacting Sales for ACS in Japan, 2015–2025
Table 152: Japan ACS Market – Drivers and Barriers, 2015–2025
Table 153: Key ACS Launch Dates
Table 154: Key Patent Expiries
Table 155: High-Prescribing Physicians (non-KOLs) Surveyed, By Country